Abstract Details

Title Atrophied T2 lesion volume and cognitive outcomes in multiple sclerosis

Topic Multiple Sclerosis

Presentation(s) P5 - Poster Session 5 (5:30 PM-6:30 PM)

Poster/Presentation
Number 15-063

Objective To investigate the association between cognitive changes, atrophied T2-lesion volume (LV), T2-LV accumulation and whole brain volume loss in multiple sclerosis (MS).

Background Cognitive dysfunction is frequent in MS, involves several domains and is associated both with inflammatory and neurodegenerative aspects of the disease. Advanced MRI techniques have broadened our understanding of neurocognitive impairment in MS, but better markers are needed. Atrophied T2-LV is a novel imaging measure that reflects the disappearance of T2 lesions into cerebrospinal fluid spaces.

Design/Methods MS patients and healthy controls (HC) were prospectively enrolled, performed MRI at the baseline and after an average of 5.5 years and were cognitively assessed at follow-up. Accumulation of conventional (T2-LV), atrophied T2-LV, and percent brain volume change (PBVC) were measured. Cognitive assessment included: Symbol Digit Modalities Test (SDMT), California Verbal Learning Test – 2^nd edition (CVLT2) and Brief Visuospatial Memory Test-Revised (BVMTR) and Paced Auditory Serial Addition Test (PASAT). Regression analyses, controlling for age and sex, assessed the relationship between MRI and cognitive outcomes.

Results 147 MS patients were recruited in the study. Atrophied T2-LV was significantly associated with PASAT (β=-0.368, p<0.001), BVMTR (β=-0.304, p<0.001), SDMT (β=-0.262, p=0.001), and CVLT2 (β=-0.197, p=0.017), while PBVC was significantly associated with BVMTR (β=0.278, p=0.001), SDMT (β=0.252, p=0.002) and PASAT (β=0.193, p=0.026), and there was a trend for association with CVLT2 (β=0.158, p=0.058). The absolute change of T2-LV was not significantly associated with any cognitive outcome.

Conclusions

Cognitive outcomes representative of processing speed, memory and executive functions were significantly associated with MRI markers of neurodegeneration. Atrophied T2-LV is a promising MRI marker, showing a significant association with all the investigated cognitive outcomes.

Authors/Disclosures
Eleonora Tavazzi, MD (Instituto Mondino) PRESENTER	No disclosure on file
Ralph H. Benedict, PhD (University At Buffalo)	Dr. Benedict has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Benedict has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Benedict has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Bristol Meyers Squibb. Dr. Benedict has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Immunic Therapeutics. Dr. Benedict has received intellectual property interests from a discovery or technology relating to health care.
Jesper Hagemeier	No disclosure on file
Dejan Jakimovski, MD, PhD (Buffalo Neuroimaging Analysis Center, University at Buffalo)	Dr. Jakimovski has nothing to disclose.
Niels Bergsland (Buffalo Neuroimaging Analysis Center / State University of New York At Buffalo)	Prof. Bergsland has nothing to disclose.
Michael G. Dwyer III, MD, PhD (Buffalo Neurological Analysis Center)	Dr. Dwyer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb. Dr. Dwyer has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Keystone Heart, Ltd. Dr. Dwyer has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. The institution of Dr. Dwyer has received research support from Novartis. The institution of Dr. Dwyer has received research support from Keystone Heart, Ltd. The institution of Dr. Dwyer has received research support from Bristol Myers Squibb. The institution of Dr. Dwyer has received research support from Roche.
Bianca Weinstock-Guttman, MD (Department of Neurology, University At Buffalo)	Dr. Weinstock-Guttman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Weinstock-Guttman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Weinstock-Guttman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis . Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genzyme &Sanofi. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen . Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bayer. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Horizon. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Weinstock-Guttman has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Weinstock-Guttman has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Janssen. Dr. Weinstock-Guttman has received personal compensation in the range of $0-$499 for serving as a Reviewer with NIH.
Robert Zivadinov, MD, PhD, FAAN (Buffalo Neuroimaging Analysis Center)	The institution of Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. The institution of Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Omnicuris. The institution of Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Myrobalan. Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. Dr. Zivadinov has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono. Dr. Zivadinov has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Bristol Myers Squibb. The institution of Dr. Zivadinov has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen.

��ɫ��

��ɫ��